Collaborations with Charité and DRFZ, and with Seoul National University, aim to identify biomarkers of disease activity and treatment response using 10x's Flex Apex platform PLEASANTON, Calif., Nov. 16, 2026 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), the life science technology leader focused on accelerating science and advancing human health, today announced two new research collaborations focused on identifying blood-based biomarkers of disease activity and treatment response for autoimmune disease.








